Carmell Corp - CTCX Quarterly EPS earnings growth

Carmell Therapeutics - graphic logo of issuer CTCX

The investment potential of Carmell Corporation (CTCX) is based on an outsourcing model for development and production, which transforms the company into a flexible research center. Quarterly EPS progress clearly demonstrates this efficiency, where the value -650.00 represents the current figure. Growth is supported by the scaling of high-margin regenerative products, although fierce competition in aesthetic medicine forces the firm to fight for its market share.

Carmell (CTCX) - Year-over-year earnings per share growth for the last twelve months from 02/21/2024 to 03/10/2025

Financial and market metric breakdowns for Carmell Corporation (CTCX)

- share price and consensus valuation forecast:
Analysis of all company metrics:Carmell Corporation
Manufactured product of Carmell Therapeutics

The market evaluates Carmell Corporation (CTCX) through the lens of its development efficiency in regenerative medicine and plasmapheresis. The quarterly EPS percentage change trend measures the growth rate of net income per share, allowing investors to filter out market noise and determine whether physician confidence is translating into real financial business sustainability.

Competitors of Carmell Corporation (CTCX)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Corp|Structure Corp (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months mimedx.com (MDXG)|Year-over-year net earnings per share growth for the last 12 months rezolutebio.com RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Year-over-year earnings per share growth for the last twelve months|ALT: Year-over-year net earnings per share growth for the last 12 months|AARD - Quarterly EPS earnings growth|SGMT: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months BioAge Labs, Inc. (BIOA)|Year-over-year earnings per share growth for the last twelve months Biomea Fusion Inc|Year-over-year earnings per share growth for the last 12 months QNCX (Quince Therapeutics)|Year-over-year net earnings per share growth for the last 12 months GUTS (Fractyl Health)|Year-over-year earnings per share growth rate for the last twelve months VTVT|Agape ATP Corporation - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PLUR|Synlogic Inc. - Quarterly EPS earnings growth|LPCN (Lipocine) - Year-over-year earnings per share growth for the last 12 months|MTNB (Matinas BioPharma Holdings Inc.) - Year-over-year net earnings per share growth for the last 12 months|SPRB (Spruce Biosciences, Inc.) - Year-over-year earnings per share growth for the last twelve months|GLTO (galecto.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS